1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Myeloma bone disease (MBD) is a devastating complication of multiple myeloma (MM).
More than 80% of MM patients suffer from destructive bony lesions, leading to pain …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

Background The combination melphalan–prednisone–thalidomide (MPT) is considered a
standard therapy for patients with myeloma who are ineligible for stem-cell transplantation …

Backround The number of cancer survivors is growing steadily and increasingly, clinical
trials are being designed to include long-term follow-up to assess not only survival, but also …

Quality of life can be divided into two dimensions, according to each subject: the subjective
or perceptive vision, and an objective health analysis. At the same time, quality of life is a …

Purpose The aim of the International Myeloma Working Group was to develop practice
recommendations for the management of multiple myeloma (MM)–related bone disease …

We sought a regimen that incorporates optimal novel agents and balances efficacy with
toxicity in transplant‐ineligible multiple myeloma (MM) patients. Our study evaluated …

Purpose: The aim of this project was to identify the nature and range of needs, as well as
levels of quality of life (QOL), of both patients living with myeloma and their partners …

Background Multiple myeloma, the second most common haematological cancer, remains
incurable. Its incidence is rising due to population ageing. Despite the impact of the disease …